De Novo Damaging Variants, Clinical Phenotypes, and Post-Operative Outcomes in Congenital Heart Disease.

TitleDe Novo Damaging Variants, Clinical Phenotypes, and Post-Operative Outcomes in Congenital Heart Disease.
Publication TypeJournal Article
Year of Publication2020
AuthorsBoskovski, MT, Homsy, J, Nathan, M, Sleeper, LA, Morton, S, Manheimer, KB, Tai, A, Gorham, J, Lewis, M, Swartz, M, Alfieris, GM, Bacha, EA, Karimi, M, Meyer, D, Nguyen, K, Bernstein, D, Romano-Adesman, A, Porter, GA, Goldmuntz, E, Chung, WK, Srivastava, D, Kaltman, JR, Tristani-Firouzi, M, Lifton, R, Roberts, AE, J Gaynor, W, Gelb, BD, Kim, R, Seidman, JG, Brueckner, M, Mayer, JE, Newburger, JW, Seidman, CE
JournalCirc Genom Precis Med
Volume13
Issue4
Paginatione002836
Date Published2020 08
ISSN2574-8300
Abstract

BACKGROUND: De novo genic and copy number variants are enriched in patients with congenital heart disease, particularly those with extra-cardiac anomalies. The impact of de novo damaging variants on outcomes following cardiac repair is unknown.

METHODS: We studied 2517 patients with congenital heart disease who had undergone whole-exome sequencing as part of the CHD GENES study (Congenital Heart Disease Genetic Network).

RESULTS: Two hundred ninety-four patients (11.7%) had clinically significant de novo variants. Patients with de novo damaging variants were 2.4 times more likely to have extra-cardiac anomalies (=5.63×10). In 1268 patients (50.4%) who had surgical data available and underwent open-heart surgery exclusive of heart transplantation as their first operation, we analyzed transplant-free survival following the first operation. Median follow-up was 2.65 years. De novo variants were associated with worse transplant-free survival (hazard ratio, 3.51; =5.33×10) and longer times to final extubation (hazard ratio, 0.74; =0.005). As de novo variants had a significant interaction with extra-cardiac anomalies for transplant-free survival (=0.003), de novo variants conveyed no additional risk for transplant-free survival for patients with these anomalies (adjusted hazard ratio, 1.96; =0.06). By contrast, de novo variants in patients without extra-cardiac anomalies were associated with worse transplant-free survival during follow-up (hazard ratio, 11.21; =1.61×10) than that of patients with no de novo variants. Using agnostic machine-learning algorithms, we identified de novo copy number variants at 15q25.2 and 15q11.2 as being associated with worse transplant-free survival and 15q25.2, 22q11.21, and 3p25.2 as being associated with prolonged time to final extubation.

CONCLUSIONS: In patients with congenital heart disease undergoing open-heart surgery, de novo variants were associated with worse transplant-free survival and longer times on the ventilator. De novo variants were most strongly associated with adverse outcomes among patients without extra-cardiac anomalies, suggesting a benefit for preoperative genetic testing even when genetic abnormalities are not suspected during routine clinical practice. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01196182.

DOI10.1161/CIRCGEN.119.002836
Alternate JournalCirc Genom Precis Med
PubMed ID32812804
PubMed Central IDPMC7439931
Grant ListU01 HL098163 / HL / NHLBI NIH HHS / United States
T32 HL007572 / HL / NHLBI NIH HHS / United States
U01 HL098188 / HL / NHLBI NIH HHS / United States
U01 HL098162 / HL / NHLBI NIH HHS / United States
/ HH / Howard Hughes Medical Institute / United States
U01 HL098153 / HL / NHLBI NIH HHS / United States
U01 HL153009 / HL / NHLBI NIH HHS / United States
U54 HG006504 / HG / NHGRI NIH HHS / United States
UL1 TR000003 / TR / NCATS NIH HHS / United States
UM1 HL128761 / HL / NHLBI NIH HHS / United States
U01 HL098123 / HL / NHLBI NIH HHS / United States
UM1 HL098147 / HL / NHLBI NIH HHS / United States
U01 HL098147 / HL / NHLBI NIH HHS / United States